Related Experiment Video
Updated: Mar 28, 2026

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
19.1K
Lamin Dysfunction Mediates Neurodegeneration in Tauopathies
Bess Frost1, Farah H Bardai1, Mel B Feany1
1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Current Biology : CB
|January 4, 2016
Summary
Tau protein aggregates in Alzheimer's disease cause lamin misregulation, leading to neuronal death. This study reveals tauopathies are neurodegenerative laminopathies, offering new therapeutic targets.
Area of Science:
- Cell Biology
- Neuroscience
- Genetics
Background:
- Lamins form the nuclear cytoskeleton, anchoring heterochromatin to the nuclear envelope and maintaining genome architecture.
- Laminopathies, caused by lamin gene mutations, result in heterochromatic DNA relaxation and cellular dysfunction.
- Tauopathies, including Alzheimer's disease, are characterized by tau protein aggregates and are associated with widespread heterochromatin relaxation.
Purpose of the Study:
- To investigate the causal role of lamin misregulation in neurodegeneration within tauopathies.
- To determine if acquired lamin dysfunction contributes to neuronal death in an in vivo model of tauopathy.
- To examine the conservation of lamin dysfunction in human tauopathy, specifically Alzheimer's disease.
Main Methods:
- Utilized an in vivo model of neurodegenerative tauopathy to study acquired lamin misregulation.
- Employed genetic manipulation to assess the impact of lamin function on neurodegeneration.
- Applied super-resolution microscopy to analyze postmortem brain tissue from human Alzheimer's disease patients.
Main Results:
- Aberrant cytoskeletal-nucleoskeletal coupling leads to acquired lamin misregulation, promoting heterochromatin relaxation and neuronal death in vivo.
- Genetic modulation of lamin function significantly altered neurodegeneration, confirming a causal role in tau-mediated neurotoxicity.
- Human Alzheimer's disease brain tissue exhibited a significantly disrupted nuclear lamina, indicating conserved lamin dysfunction.
Conclusions:
- Tauopathies are identified as a class of neurodegenerative laminopathies.
- Aberrant lamin function represents a key pathway mediating neuronal death in tauopathies.
- This research uncovers a novel therapeutic target for currently untreatable neurodegenerative disorders like Alzheimer's disease.
Related Concept Videos
Long-term Depression
33.7K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.7K
Long-term Depression
3.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
3.6K
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Neural Regulation
44.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.7K

